MedTrace Logo

Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor

NCT02430233 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2023-02-28

No results posted yet for this study

Summary

Patients diagnosed with arrested pre-term labor following tocolytics at 24-34 gestational weeks will be randomly allocated to receive either vaginal micronized progesterone 400 mg/day or no treatment.

Conditions

  • Preterm Labor

Interventions

DRUG

micronized progesterone 400 mg (Utrogestan)

participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-19
Primary Completion
2023-02-27
Completion
2023-02-27

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02430233 on ClinicalTrials.gov